Brief: Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

Axsome Therapeutics

25/03/2025 11:45

March 25 (Reuters) - Axsome Therapeutics Inc AXSM.O:

AXSOME THERAPEUTICS ANNOUNCES FOCUS PHASE 3 TRIAL OF SOLRIAMFETOL IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) ACHIEVES PRIMARY ENDPOINT

AXSOME THERAPEUTICS INC: WELL TOLERATED WITH SAFETY PROFILE GENERALLY CONSISTENT WITH PRIOR SOLRIAMFETOL TRIALS

AXSOME THERAPEUTICS INC: STATISTICALLY SIGNIFICANT REDUCTION IN OVERALL ADHD DISEASE SEVERITY AS MEASURED BY CGI-S SCORE COMPARED TO PLACEBO

AXSOME THERAPEUTICS : STATISTICALLY SIGNIFICANT IMPROVEMENT IN ADHD SYMPTOMS AS MEASURED BY AISRS TOTAL SCORE COMPARED TO PLACEBO

Source text: ID:nGNX7rXL64

Further company coverage: AXSM.O

 ((Reuters.Briefs@thomsonreuters.com;))